Biotech

All Articles

Pfizer takes $230M attacked after axing neglected DMD genetics therapy

.Pfizer's phase 3 Duchenne muscular dystrophy (DMD) gene treatment failing has blown a $230 million ...

AC Immune finds 'landmark' prospective in Alzheimer's medicine data

.After much more than 20 years of work on neurodegenerative health conditions, Swiss biotech a/c Imm...

GSK drops ph. 2 HPV vaccination over shortage of best-in-class prospective

.GSK has ditched a phase 2 individual papillomavirus (HPV) injection from its pipe after deciding th...

OS Treatments refiles $6M IPO to cash HER2 medication, preclinical ADCs

.Operating system Therapies will note on the NYSE American sell swap today using a $6.4 million IPO ...

ALX's waning CD47 action fee sends supply spiraling down

.ALX Oncology's period 2 stomach cancer action cost has damaged. After seeing its CD47 blocker easil...

Ionis centers eye illness coming from intendeds of Roche-partnered prospect after data dissatisfy

.Another of Ionis Pharmaceuticals' crucial midphase readouts has fallen short of desires, urging the...

Biogen's CEO claimed no unsafe sell 2023. He prepares to become daring

.While Biogen's pharma peers are searching for late-stage resources with little bit of danger, CEO C...

Instil refills pipeline in $2B biobucks manage ImmunOnco

.Instil Biography has been a biotech seeking a pipeline after it ditched its lead resources over the...

Biogen walks away from Denali Alzheimer's collab

.Biogen has returned rights to an early Alzheimer's ailment course to Denali Therapeutics, going out...

Takeda water faucets brand new mind people oncology service-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our roundup of notable management hirings, shootings as ...